X4 Pharmaceuticals, Inc (XFOR) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
61 NORTH BEACON STREET BOSTON, MA 02134 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2025 MRQ | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 102,100 | 114,200 | 121,718 | 81,787 | 78,708 | 126,184 | |||
| Cash and cash equivalent | 55,699 | 99,216 | 121,718 | 81,787 | 78,708 | 126,184 | |||
| Other undisclosed cash, cash equivalents, and short-term investments | 46,401 | 14,984 | |||||||
| Restricted cash and investments | 250 | 285 | 264 | ||||||
| Receivables | 1,070 | ||||||||
| Inventory, net of allowances, customer advances and progress billings | 2,817 | ||||||||
| Inventory | 2,817 | ||||||||
| Other undisclosed current assets | 6,188 | 7,626 | 6,674 | 6,091 | 4,335 | 3,094 | |||
| Total current assets: | 112,175 | 122,076 | 128,677 | 87,878 | 83,307 | 129,278 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 4,065 | 5,650 | 7,229 | 8,710 | 7,960 | 1,959 | |||
| Property, plant and equipment | 776 | 745 | 1,104 | 1,514 | 1,237 | 403 | |||
| Intangible assets, net (including goodwill) | 27,351 | 17,351 | 17,351 | 17,351 | 27,109 | 27,109 | |||
| Goodwill | 17,351 | 17,351 | 17,351 | 17,351 | 27,109 | 27,109 | |||
| Intangible assets, net (excluding goodwill) | 10,000 | ||||||||
| Other noncurrent assets | 2,080 | 1,436 | 1,225 | 1,723 | 3,258 | 1,949 | |||
| Total noncurrent assets: | 34,272 | 25,182 | 26,909 | 29,298 | 39,564 | 31,420 | |||
| TOTAL ASSETS: | 146,447 | 147,258 | 155,586 | 117,176 | 122,871 | 160,698 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 31,626 | 21,763 | 19,811 | 12,153 | 11,162 | 8,549 | |||
| Accounts payable | 8,621 | 8,947 | 7,777 | 4,283 | 3,144 | 2,088 | |||
| Accrued liabilities | 23,005 | 12,816 | 12,034 | 7,870 | 8,018 | 6,461 | |||
| Deferred revenue | |||||||||
| Debt | 1,315 | 795 | 898 | ||||||
| Other undisclosed current liabilities | 1,251 | 1,099 | 1,198 | 1,075 | 786 | ||||
| Total current liabilities: | 32,877 | 22,862 | 22,324 | 14,023 | 11,948 | 9,447 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 54,570 | 32,304 | 37,915 | 4,484 | 21,918 | ||||
| Long-term debt, excluding current maturities | 54,570 | 32,304 | 33,139 | 20,000 | |||||
| Liabilities, other than long-term debt | 15,996 | 18,727 | 26,907 | 826 | 462 | 16 | |||
| Deferred revenue | |||||||||
| Other liabilities | 831 | 432 | 173 | 826 | 462 | 16 | |||
| Operating lease, liability | 1,410 | 2,612 | 3,603 | 4,776 | 4,484 | 1,918 | |||
| Derivative instruments and hedges, liabilities | 13,755 | 15,683 | 23,131 | ||||||
| Other undisclosed noncurrent liabilities | 75,425 | 33,178 | 97 | ||||||
| Total noncurrent liabilities: | 91,421 | 73,297 | 59,211 | 38,741 | 38,124 | 22,031 | |||
| Total liabilities: | 124,298 | 96,159 | 81,535 | 52,764 | 50,072 | 31,478 | |||
| Equity | |||||||||
| Equity, attributable to parent | 22,149 | 51,099 | 74,051 | 64,412 | 72,799 | 129,220 | |||
| Common stock | 171 | 167 | 122 | 28 | 16 | 16 | |||
| Additional paid in capital | 537,455 | 528,956 | 450,786 | 347,374 | 267,077 | 261,367 | |||
| Accumulated other comprehensive loss | (122) | (119) | (119) | (119) | (119) | (119) | |||
| Accumulated deficit | (515,355) | (477,905) | (376,738) | (282,871) | (194,175) | (132,044) | |||
| Total equity: | 22,149 | 51,099 | 74,051 | 64,412 | 72,799 | 129,220 | |||
| TOTAL LIABILITIES AND EQUITY: | 146,447 | 147,258 | 155,586 | 117,176 | 122,871 | 160,698 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 2,557 | 195 | 196 | 196 | 3,000 | 14 | ||
| Sublease income | 195 | 196 | 196 | 194 | 14 | |||
| Cost of revenue | (797) | |||||||
| Gross profit: | 1,760 | 195 | 196 | 196 | 3,000 | 14 | ||
| Operating expenses | (38,161) | (107,522) | (87,569) | (85,107) | (62,874) | (51,703) | ||
| Other undisclosed operating income (loss) | (195) | (196) | (196) | (14) | ||||
| Operating loss: | (36,401) | (107,522) | (87,569) | (85,107) | (59,874) | (51,703) | ||
| Nonoperating income (expense) | (739) | 6,433 | (6,270) | (3,572) | (2,109) | (1,104) | ||
| Investment income, nonoperating | 5,769 | 4,582 | 219 | 10 | 273 | 1,197 | ||
| Other nonoperating income (expense) | 332 | 554 | (4,197) | 426 | 905 | 517 | ||
| Interest and debt expense | (8,768) | (5,777) | (3,993) | (3,642) | (162) | (566) | ||
| Other undisclosed income from continuing operations before equity method investments, income taxes | 162 | 566 | ||||||
| Loss from continuing operations before equity method investments, income taxes: | (45,908) | (106,866) | (97,832) | (92,321) | (61,983) | (52,807) | ||
| Other undisclosed income from continuing operations before income taxes | 8,768 | 5,777 | 3,993 | 3,642 | ||||
| Loss from continuing operations before income taxes: | (37,140) | (101,089) | (93,839) | (88,679) | (61,983) | (52,807) | ||
| Income tax expense | (310) | (78) | (28) | (17) | (148) | |||
| Loss from continuing operations: | (37,450) | (101,167) | (93,867) | (88,696) | (62,131) | (52,807) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (88,696) | (62,131) | (52,807) | |
| Net loss attributable to parent: | (37,450) | (101,167) | (93,867) | (88,696) | (62,131) | (52,807) | ||
| Preferred stock dividends and other adjustments | (592) | |||||||
| Other undisclosed net loss available to common stockholders, basic | (2,546) | (13,943) | ||||||
| Net loss available to common stockholders, diluted: | (37,450) | (101,167) | (96,413) | (102,639) | (62,131) | (53,399) | ||
Comprehensive Income ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (37,450) | (101,167) | (93,867) | (88,696) | (62,131) | (52,807) | ||
| Other comprehensive loss | ||||||||
| Other undisclosed comprehensive loss | ||||||||
| Comprehensive loss: | (37,450) | (101,167) | (93,867) | (88,696) | (62,131) | (52,807) | ||
| Other undisclosed comprehensive loss, net of tax, attributable to parent | (3) | (119) | ||||||
| Comprehensive loss, net of tax, attributable to parent: | (37,453) | (101,167) | (93,867) | (88,696) | (62,131) | (52,926) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.